Back to search results

Text Messages to Improve Oral Chemotherapy for ALL and T-cell Lymphoblastic Lymphoma

This study is looking at whether text messages can help adolescents and adults with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma take their oral chemotherapy (mercaptopurine and methotrexate) as prescribed. You could be eligible if you are 15 years or older, have ALL or T-cell lymphoblastic lymphoma, and are starting maintenance treatment with mercaptopurine and methotrexate. The study will first check if text messages are acceptable to participants. Then, it will compare how well people take their medicine when they receive daily text messages versus standard care. The goal is to see if daily text messages improve how consistently people take their oral chemotherapy during the first treatment cycle. The current recruitment status is unclear.

Study design
This is a single-center study with two phases, planning to enroll 48 participants. It is an interventional study, meaning participants will receive a specific intervention.
What's involved
In the pilot phase, you would complete questionnaires for 28 days. The efficacy phase will compare adherence to oral chemotherapy for 84 days.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for the efficacy phase is measured 84 days after enrollment to that phase. The pilot phase endpoint is measured 28 days after enrollment to that phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06446661

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Recruiting
NAAges 15+Interventional
University of Chicago
~48 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:High IntensityNo Text MessagingsLow Intensity Text Messaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To compare adherence to oral chemotherapy between study groups for first treatment cycle (Efficacy Phase)
Measured over 84 days after completion of enrollment to efficacy phase of study
+1 more outcome measured

Conditions

Acute Lymphoblastic Leukemia
T-cell Lymphoblastic Lymphoma

Explore related trials

Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma

NCT06446661

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Austin Wesevich · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Clinical Trials Intake
[email protected]
1-855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age of 15 years or older at time of enrollment
Diagnosed with ALL or T-cell lymphoblastic lymphoma
Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.

Exclusion

Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
Patient does not wish to participate
Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

What this trial measures

  • To compare adherence to oral chemotherapy between study groups for first treatment cycle (Efficacy Phase)84 days after completion of enrollment to efficacy phase of study

    Adherence to chemotherapy regimen will be measured based on combined data from 8.1 Medication Event Monitoring System (MEMS) TrackCap devices which measure the number of times pill bottles are opened, responses to Medication Adherence Report Scale (MARS-5) questionnaire, number of pharmacy fills, and mean corpuscular volume (MCV) .

  • Feasibility of text message interventions to improve adherence to oral chemotherapy (Pilot Phase)28 days after completion of enrollment to pilot phase of study

    Feasibility will be measured based on participant responses to validated questionnaires - Feasibility of intervention measure (FIM) and Acceptability of intervention measure (AIM). Both forms are 4 items scored on a 5 point Likert scale. Scores greater than or equal to 16 will determine whether the intervention is feasible.